

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	RESAPP HEALTH LIMITED
ABN	51 094 468 318

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Tony Keating
Date of last notice	7 July 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Not applicable
Date of change	10 November 2016
No. of securities held prior to change	5,000,000 Options (\$0.025; 2 July 2020) 5,000,000 Options (\$0.05; 2 July 2020) 10,000,000 Options (\$0.10; 2 July 2020)
Class	Director Incentive Options
Number acquired	1,800,000 Tranche 1 Director Incentive Options exercisable at \$0.45; expiring 10 November 2019; and 2,000,000 Tranche 2 Director Incentive Options exercisable at \$0.75; expiring 10 November 2019
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Director Incentive Options issued to provide an incentive and reward for Directors for their contributions to the Company as set out in the Company's Notice of Annual General Meeting.
No. of securities held after change	5,000,000 Options (\$0.025; 2 July 2020) 5,000,000 Options (\$0.05; 2 July 2020) 10,000,000 Options (\$0.10; 2 July 2020) 1,800,000 Options (\$0.45; 10 November 2019) 2,00,000 Options (\$0.75; 10 November 2019)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Director Incentive Options issued as approved by Shareholders at the Annual General Meeting held on 2 November 2016.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Not applicable
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	RESAPP HEALTH LIMITED
ABN	51 094 468 318

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Roger Aston
Date of last notice	7 July 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	10 November 2016
No. of securities held prior to change	8,437,500 Ordinary Fully Paid Shares (escrowed until 14 July 2017) 8,437,500 Performance Shares (escrowed until 14 July 2017)
Class	Director Incentive Options
Number acquired	1,800,000 Tranche 1 Director Incentive Options exercisable at \$0.45; expiring 10 November 2019; and 1,800,000 Tranche 2 Director Incentive Options exercisable at \$0.75; expiring 10 November 2019

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Director Incentive Options issued to provide an incentive and reward for Directors for their contributions to the Company as set out in the Company's Notice of Annual General Meeting.
No. of securities held after change	<p>Roger Aston:</p> <ul style="list-style-type: none"> • 1,800,000 Director Incentive Options (\$0.45; 10 November 2019) • 1,800,000 Director Incentive Options (\$0.75; 10 November 2019) <p>Newtonmore Biosciences Pty Ltd:</p> <ul style="list-style-type: none"> • 8,437,500 Ordinary Fully Paid Shares (escrowed until 14 July 2017) • 8,437,500 Performance Shares (escrowed until 14 July 2017)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Director Incentive Options issued as approved by Shareholders at the Annual General Meeting held on 2 November 2016.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Not applicable
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	RESAPP HEALTH LIMITED
ABN	51 094 468 318

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Brian Leedman
Date of last notice	18 March 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	10 November 2016
No. of securities held prior to change	<p>Brian Leedman & Natasha Leedman:</p> <ul style="list-style-type: none"> • 6,810,000 Ordinary Fully Paid Shares; • 18,750,000 Ordinary Fully Paid Shares (escrowed until 14 July 2017) • 18,750,000 Performance Shares (escrowed until 14 July 2017) • 1,875,000 Unlisted Options (\$0.026; 31 Dec 2016) (escrowed until 14 July 2017) <p>Tashtech Pty Ltd:</p> <ul style="list-style-type: none"> • 4,500,000 Ordinary Fully Paid Shares (escrowed until 14 July 2017) • 4,500,000 Performance Shares (escrowed until 14 July 2017)

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Director Incentive Options
Number acquired	1,800,000 Tranche 1 Director Incentive Options exercisable at \$0.45; expiring 10 November 2019; and 1,800,000 Tranche 2 Director Incentive Options exercisable at \$0.75; expiring 10 November 2019
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Director Incentive Options issued to provide an incentive and reward for Directors for their contributions to the Company as set out in the Company's Notice of Annual General Meeting.
No. of securities held after change	<p>Brian Leedman & Natasha Leedman:</p> <ul style="list-style-type: none"> • 6,810,000 Ordinary Fully Paid Shares; • 18,750,000 Ordinary Fully Paid Shares (escrowed until 14 July 2017) • 18,750,000 Performance Shares (escrowed until 14 July 2017) • 1,875,000 Unlisted Options (\$0.026; 31 December 16) (escrowed until 14 July 2017) • 1,800,000 Director Incentive Options (\$0.45; 10 November 2019) • 1,800,000 Director Incentive Options (\$0.75; 10 November 2019) <p>Tashtech Pty Ltd:</p> <ul style="list-style-type: none"> • 4,500,000 Ordinary Fully Paid Shares (escrowed until 14 July 2017) • 4,500,000 Performance Shares (escrowed until 14 July 2017)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Director Incentive Options issued as approved by Shareholders at the Annual General Meeting held on 2 November 2016.

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Not applicable
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	RESAPP HEALTH LIMITED
ABN	51 094 468 318

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Chris Ntoumenopoulos
Date of last notice	7 July 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Sobol Capital Pty Ltd <BOC Trust> – director, shareholder and beneficiary
Date of change	10 November 2016
No. of securities held prior to change	2,109,375 (escrowed for 24 months to 14 July 2017)
Class	Director Incentive Options
Number acquired	1,800,000 Tranche 1 Director Incentive Options exercisable at \$0.45; expiring 10 November 2019; and 1,800,000 Tranche 2 Director Incentive Options exercisable at \$0.75; expiring 10 November 2019
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Director Incentive Options issued to provide an incentive and reward for Directors for their contributions to the Company as set out in the Company's Notice of Annual General Meeting.

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	2,109,375 Shares 1,800,000 Director Incentive Options exercisable at \$0.45; expiring 10 November 2019; and 1,800,000 Director Incentive Options exercisable at \$0.75; expiring 10 November 2019
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Director Incentive Options issued as approved by Shareholders at the Annual General Meeting held on 2 November 2016.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Not applicable
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.